Livzon Pharmaceutical Group Inc (000513) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Livzon Pharmaceutical Group Inc stock ¥49.84, price ¥31.67, upside +57.4%, quality 80 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
60‑month range ¥24.65 – ¥41.30 · fair‑value band ¥37.38 – ¥62.30 · the ¥31.67 price screens below the ¥49.84 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.
Follow Livzon Pharmaceutical Group in your weekly email
Every Wednesday you see whether Livzon Pharmaceutical Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally.
Show moreShow less
The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate for the psychiatric and neurological field; and shenqi fuzheng injection and anti-viral granules for the traditional Chinese medicine field.
It also produces APIs and intermediates, such as mevastatin, acarbose, teicoplanin, gentamycin sulfate, phenylalanine, vancomycin hydrochloride, daptomycin, milbemycin oxime, and ceftriaxone sodium, as well as diagnostic reagents such as diagnostic kits for IgM antibody to mycoplasma pneumonia; diagnostic kits for human immunodeficiency virus antibody; and livzon antinuclear antibody test kits.
In addition, the company offers nucleic acid test kits; livzon interferon-gamma release assays test kits; influenza A/B virus antigen detection kits; and treponema pallidum antibody detection kits.
Further, it provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, stomatitis granules, biochemical and polypeptide APIs, and antibiotic APIs, as well as diagnostic equipment.
Livzon Pharmaceutical Group Inc. was incorporated in 1985 and is headquartered in Zhuhai, China.
Stock analysis
Livzon Pharmaceutical Group Inc (000513) currently trades at ¥31.67, while our model-based Fair Value estimate is ¥49.84, implying the stock looks roughly 36% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ¥66.56 per share, and 20 of the 26 models we run sit above the ¥31.67 price.
Bear case: the Asset-Based group reads lowest at ¥6.74, and 6 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: ¥37.38 (bear) to ¥62.30 (bull), the price of ¥31.67 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 80/100 (high quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Livzon Pharmaceutical Group Inc reported revenue of 11.9B CNY in FY2025 versus 12.1B CNY in FY2021, a compound −0.3%/yr. Reported net income was 2.0B CNY in FY2025, compounding +3.3%/yr from FY2021.
Key figures
Market cap 28.3B CNY (≈ $4.2B) Mid · P/E ratio 16.2 · P/S ratio 2.77 · EPS (TTM) ¥1.73 · Dividend yield 4.5% · Net margin 15.2% · Return on equity 12.4% · Return on assets (EBIT) 10.4% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 61 out of 100 (low confidence).
What moves the price
The share trades about 9% below its 52-week high and 26% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 57%, 000513 screens cheaper than that median.
Fair Value models
Bear¥37.38Fair Value ¥49.84Bull¥62.30
Price ¥31.67 · Upside +57.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.2622 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.65/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+0.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.5%
Start year 2020 (pandemic). Over 10 years: +6.0% a year
Revenue growth 28 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+8.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+4.4%
Dividend (yield on the price)4.5%
Per share before 1997divided by the spin-off factor 1.243
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.4.4% vs 12.0%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.24% → 22%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−8.8%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
−2.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −10.4% a year for the price and −4.5% for the forecasts.
Compare Livzon Pharmaceutical Group Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks
Beats the industry median on 11/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score80 · Top 25%
Fair Value upside+57.4% · Top 25%
Profitability
Return on equity (12 months)12.4% · Above median
Return on assets8.4% · Top 25%
Net margin (12 months)15.2% · Top 25%
Operating margin (12 months)19.9% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)−18.4% · Bottom 25%
Dividend yield (12 months)4.5% · Top 25%
Balance sheet
Debt / equity0.05× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Livzon Pharmaceutical Group Inc Fair Value". https://www.fairvalue-calculator.com/stock/000513
Frequently asked questions
Is Livzon Pharmaceutical Group Inc (000513) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of ¥49.84 versus a price of ¥31.67, about +57% upside (undervalued).
What is the fair value of 000513?
Our model-based fair value for Livzon Pharmaceutical Group Inc is ¥49.84 (as of Nov 14, 2026), built from audited fundamentals. The current price: ¥31.67.
What is the quality score of 000513?
Livzon Pharmaceutical Group Inc has a Quality Score of 80/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Livzon Pharmaceutical Group Inc (000513)?
Our model-based price target is the fair value of ¥49.84 (as of Nov 14, 2026) from 26 valuation models. Cautious scenario ¥37.38, optimistic scenario ¥62.30. It is a calculation from audited fundamentals, not an analyst target.
What is the Livzon Pharmaceutical Group Inc stock forecast for 2026?
Our models put fair value at ¥49.84, about +57% upside versus a price of ¥31.67 (undervalued). Cautious scenario ¥37.38, optimistic scenario ¥62.30. The calculation is refreshed regularly with new filings.
What is the revenue of Livzon Pharmaceutical Group Inc (000513)?
Livzon Pharmaceutical Group Inc reported trailing-twelve-month revenue of about 10.2B CNY (latest available figure, as of Nov 14, 2026).
Does Livzon Pharmaceutical Group Inc pay a dividend?
Livzon Pharmaceutical Group Inc currently shows a dividend yield of 4.52% relative to its recent price (as of Nov 14, 2026).
How much is the dividend of Livzon Pharmaceutical Group Inc (000513) and when is the ex-dividend date?
Livzon Pharmaceutical Group Inc pays a dividend of ¥1.43 per share a year, a dividend yield of 4.5%. The last ex-dividend date was Oct 14, 2026. A dividend has been paid every year since 2008. The payout ratio is 82.7% of earnings. Free cash flow covers the dividend 3.10 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Livzon Pharmaceutical Group Inc (000513)?
Today's price is already fair in a discounted-cash-flow model if free cash flow at Livzon Pharmaceutical Group Inc shrinks by 8.8 % per year for five years (discount rate 9.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 2.5 % per year. As of Nov 14, 2026.
What discount rate (WACC) does the fair value of 000513 use?
Our models discount Livzon Pharmaceutical Group Inc at 9.1 %: a base by market capitalisation (mid), damped by beta 0.09, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Livzon Pharmaceutical Group Inc that is -8.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.1 %) and the same formula as our fair value.
How much growth has Livzon Pharmaceutical Group Inc (000513) delivered so far?
Over the past 5 years revenue at Livzon Pharmaceutical Group Inc grew 2.5 % a year. The price currently implies free-cash-flow growth of -8.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Livzon Pharmaceutical Group Inc (000513) growing?
The median revenue growth in the sector is +5.8 % a year. That is the yardstick for the growth priced into Livzon Pharmaceutical Group Inc (-8.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Livzon Pharmaceutical Group Inc (000513)?
The free-cash-flow yield on the price is 9.21 %: that much free cash flow Livzon Pharmaceutical Group Inc produces per unit of market value. When it exceeds the discount rate of our models (9.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Livzon Pharmaceutical Group Inc (000513)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Livzon Pharmaceutical Group Inc it is ¥49.84 per share (as of Nov 14, 2026), against a price of ¥31.67. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Livzon Pharmaceutical Group Inc stock overvalued or undervalued in 2026?
As of Nov 14, 2026, 000513 trades below its calculated fair value: price ¥31.67, fair value ¥49.84, a gap of about +57% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 000513?
No. The price is what the market pays today (¥31.67); the fair value is what the company's own numbers justify (¥49.84). For Livzon Pharmaceutical Group Inc the two are ¥18.17 per share apart. That gap is exactly why we show both numbers side by side.
How much is Livzon Pharmaceutical Group Inc worth?
The market values Livzon Pharmaceutical Group Inc at about 28.3B CNY (market capitalisation, as of Nov 14, 2026). Per share that is ¥31.67; our models calculate a fair value of ¥49.84 per share.
What do the bullish and bearish scenarios say about 000513?
Our models span a range for Livzon Pharmaceutical Group Inc: cautious scenario ¥37.38, base ¥49.84, optimistic ¥62.30 per share (as of Nov 14, 2026, price ¥31.67). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 000513?
Livzon Pharmaceutical Group Inc trades at a price-to-earnings ratio of 16.2 (as of Nov 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥49.84 is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2019 to 2025), reported earnings, FY2025 ex one-offs: 17.0. Other multiples: P/B 2.0, P/S 2.8, EV/EBITDA 7.7.
How solid is the balance sheet of Livzon Pharmaceutical Group Inc (000513)?
Balance-sheet figures for Livzon Pharmaceutical Group Inc (as of Nov 14, 2026): return on equity 12.4%, debt of 0.05 per unit of equity. They feed the Quality Score of 80/100, which measures business quality independently of the share price.
How far is 000513 from its 52-week high?
Livzon Pharmaceutical Group Inc trades at ¥31.67, about 9% below its 52-week high of ¥34.67 and 26% above the low of ¥25.07 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of ¥49.84 is for.
Which stocks are comparable to Livzon Pharmaceutical Group Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Livzon Pharmaceutical Group Inc stock attractive at the current price?
The data as of Nov 14, 2026: price ¥31.67, calculated fair value ¥49.84 (+57%), Quality Score 80/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 000513 calculated?
We run Livzon Pharmaceutical Group Inc through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥49.84 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1% above its aggregate fair value. Livzon Pharmaceutical Group Inc currently trades 36% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Livzon Pharmaceutical Group Inc (000513)?
The closing price on Nov 13, 2026 was ¥31.67. Our model-based fair value is ¥49.84, about +57% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Livzon Pharmaceutical Group Inc right now?
The rarer combination: high quality (80/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (¥37.38). The market is more pessimistic than our downside scenario.
Where does the earnings growth of Livzon Pharmaceutical Group Inc (000513) come from?
Earnings per share at Livzon Pharmaceutical Group Inc grew 12.8 % a year from 2014 to 2025. Broken into its drivers: revenue per share +6.2 %, EBIT margin +8.0 %, tax rate −0.2 %, residual (interest, one-offs) −1.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Livzon Pharmaceutical Group Inc
How large is the market capitalisation of Livzon Pharmaceutical Group Inc (000513)?
The market capitalisation of Livzon Pharmaceutical Group Inc is 28.3B CNY (≈ $4.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Livzon Pharmaceutical Group Inc (000513)?
The price-to-sales ratio of Livzon Pharmaceutical Group Inc is 2.77 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Livzon Pharmaceutical Group Inc (000513)?
Earnings per share at Livzon Pharmaceutical Group Inc are ¥1.73 (price ÷ EPS = P/E 16.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Livzon Pharmaceutical Group Inc (000513)?
The dividend yield of Livzon Pharmaceutical Group Inc is 4.5% (payout 82.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Livzon Pharmaceutical Group Inc (000513)?
The net margin of Livzon Pharmaceutical Group Inc is 15.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Livzon Pharmaceutical Group Inc (000513)?
The return on equity (ROE) of Livzon Pharmaceutical Group Inc is 12.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Livzon Pharmaceutical Group Inc (000513)?
On an EBIT basis the return on assets of Livzon Pharmaceutical Group Inc is 10.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Livzon Pharmaceutical Group Inc (000513)?
The operating margin of Livzon Pharmaceutical Group Inc is 19.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Livzon Pharmaceutical Group Inc (000513)?
Revenue at Livzon Pharmaceutical Group Inc is down 18.4% versus a year earlier (3y avg −1.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Livzon Pharmaceutical Group Inc (000513)?
Earnings per share at Livzon Pharmaceutical Group Inc are down 24.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Livzon Pharmaceutical Group Inc (000513) hold?
Livzon Pharmaceutical Group Inc holds more cash than debt, 5.5B CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Livzon Pharmaceutical Group Inc in the live analysis
One click puts Livzon Pharmaceutical Group Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 14, 2026